Open AccessReal-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease
Author(s) -
Nicole Quah Qin Xian,
Ahmed Alnahrawy,
Rashmi Akshikar,
Vickie Lee
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s305717
Subject(s) - medicine , visual acuity , optic neuropathy , retrospective cohort study , adverse effect , dosing , clinical trial , surgery , ophthalmology , optic nerve
There is no universal consensus on second-line agents for the treatment of moderate/severe to sight-threatening thyroid eye disease (TED) to maintain remission after first-line intravenous methylprednisolone (IVMP). This study investigates the efficacy and safety of mycophenolate mofetil (MMF) in TED patients in a real-world setting and over a longer period than previous randomized controlled trials.